<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00441350</url>
  </required_header>
  <id_info>
    <org_study_id>CS866CM-B-E303</org_study_id>
    <nct_id>NCT00441350</nct_id>
  </id_info>
  <brief_title>Olmesartan/HCTZ 40/12.5 mg Combination Therapy Versus Olmesartan Medoxomil 40 mg Monotherapy in Essential Hypertension</brief_title>
  <official_title>Phase III Study Evaluating the Efficacy and Safety of Olmesartan Medoxomil/Hydrochlorothiazide 40/12.5 mg Combination Therapy Versus Olmesartan Medoxomil 40 mg Monotherapy in Patients With Essential Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Menarini Group</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Menarini Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study was to assess the anti-hypertensive effect of OM/HCTZ&#xD;
      40/12.5 mg combination therapy compared to OM 40 mg monotherapy in lowering sitting diastolic&#xD;
      BP in hypertensive patients after 8 weeks of double-blind treatment.&#xD;
&#xD;
      The study consisted of two sequential phases of 8 weeks duration each:&#xD;
&#xD;
      During the first phase, OM 40 mg monotherapy was compared with OM/HCTZ 40/12.5 mg in order to&#xD;
      evaluate the additional benefit of OM/HCTZ 40/12.5 mg in the treatment of essential moderate&#xD;
      to severe hypertension.&#xD;
&#xD;
      During the second phase, patients whose BP proved to be insufficiently controlled by the OM&#xD;
      40 mg monotherapy were to start OM/HCTZ 40/12.5 mg combination therapy while patients whose&#xD;
      BP proved to be insufficiently controlled by the OM/HCTZ 40/12.5 mg combination were to be&#xD;
      up-titrated to the OM/HCTZ 40/25 mg combination to evaluate the additional benefit of the&#xD;
      up-titrated combination.&#xD;
&#xD;
      The study was be conducted by qualified and experienced personnel with adherence to GCP,&#xD;
      current guidelines on the design of studies in hypertension, the applicable regulatory&#xD;
      requirements and the ethical principles based on the Declaration of Helsinki.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Methodology:&#xD;
&#xD;
      After the signature of the informed consent, patients were screened for eligibility and&#xD;
      eligible patients entered into a pre-randomisation period consisting of a taper-off phase of&#xD;
      approximately 1-2 weeks (during which patients treated for hypertension were to discontinue&#xD;
      their antihypertensive therapy) followed by a 2-week single-blind placebo run-in phase (Visit&#xD;
      1). After conclusion of the placebo run-in phase (Visit 2), eligible patients were randomised&#xD;
      to the double-blind active treatment period which consisted of two phases:&#xD;
&#xD;
      First double-blind treatment phase (Phase A, from Randomisation to Week 8):&#xD;
&#xD;
      Eligible patients with mean sitting sBP ≥ 160 and ≤ 200 mmHg and dBP ≥ 100 mmHg and ≤ 120&#xD;
      mmHg were randomised in a 1:2 ratio to receive either OM 40 mg or OM/HCTZ 40/12.5 mg for a&#xD;
      total of 8 weeks of treatment (Phase A). Study visits were held after 4 and 8 weeks of&#xD;
      double-blind active treatment (Visit 3 and 4, respectively). After 8 weeks (Visit 4),&#xD;
      patients reaching the BP goal of &lt; 140/90 mmHg or &lt; 130/80 mmHg for diabetics were considered&#xD;
      as responders. All patients (responders and non-responders) then entered into the titration&#xD;
      phase of the study (Phase B):&#xD;
&#xD;
      Second double-blind treatment phase/titration phase (Phase B, from Week 8 to Week 16):&#xD;
&#xD;
      Treatment assignment in the second part of the study was based on the following criteria:&#xD;
&#xD;
        -  Responders to Phase A treatment continued to receive the same double-blind treatment for&#xD;
           an additional 8 weeks.&#xD;
&#xD;
        -  Non-responders Phase A treatment had their treatment assigned as follows:&#xD;
&#xD;
             -  Non-responders to OM 40 mg were treated with OM/HCTZ 40/12.5 mg for an additional 8&#xD;
                weeks.&#xD;
&#xD;
             -  Non-responders to OM/HCTZ 40/12.5 mg were uptitrated to OM/HCTZ 40/25 mg for an&#xD;
                additional 8 weeks. During Phase B of the study, visits were held 12 and 16 weeks&#xD;
                after randomisation (Visits 5 and 6, respectively).&#xD;
&#xD;
      The study ended at Visit 6 and a final examination was performed. A safety follow-up (SFU)&#xD;
      telephone contact was performed 2 weeks after the end of the treatment. An SFU visit was&#xD;
      performed if deemed necessary by the investigator.&#xD;
&#xD;
      Sphygmomanometer was used for BP measurement throughout the trial. BP was measured at all&#xD;
      visits as nearly as possible at the same time of the day as trough readings (24 ± 2 h after&#xD;
      last drug intake) after a 10 minute rest period. Three separate sitting BP measurements were&#xD;
      taken at least 1 minute apart from each other. The 3 results were then averaged and rounded&#xD;
      to a whole integer.&#xD;
&#xD;
      Patients with sBP values &gt; 200 mmHg and/or dBP values &gt; 120 mmHg at any time during the study&#xD;
      were to be discontinued from the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>dBP Change After 8 Weeks Phase A</measure>
    <time_frame>Eight weeks</time_frame>
    <description>Reduction in Mean Trough Sitting dBP (mmHg) from Baseline (Week 0) to Week 8</description>
  </primary_outcome>
  <primary_outcome>
    <measure>sBP Change After 8 Weeks Phase A</measure>
    <time_frame>Eight weeks</time_frame>
    <description>Reduction in Mean Trough Sitting sBP (mmHg) from Baseline (Week 0) to Week 8</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>dBP Change After 8 Weeks Phase B</measure>
    <time_frame>Eight weeks</time_frame>
    <description>Reduction in trough sitting diastolic blood pressure after 8 weeks of additional treatment, depending on Phase A treatment and outcome (responder/non-responder).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sBP Change After 8 Weeks Phase B</measure>
    <time_frame>Eight weeks</time_frame>
    <description>Reduction in trough sitting systolic blood pressure after 8 weeks of additional treatment, depending on Phase A treatment and outcome (responder/non-responder).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1004</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>OM 40</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Olmesartanmedoxomil (OM)40 mg tablets.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OM/HCTZ 40/12.5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Olmesartanmedoxomil (OM) /Hydrochlorothiazide (HCTZ)40/12.5 mg tablets.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OM 40</intervention_name>
    <description>Initially patients were to be treated with Olmesartanmedoxomil (OM)40 mg tablets once daily for 8 weeks. After 8 weeks non-responders were to be uptitrated to OM/HCTZ 40/12.5 mg and responders remained on the previous therapy for further 8 weeks.</description>
    <arm_group_label>OM 40</arm_group_label>
    <other_name>Treatment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OM/HCTZ 40/12.5</intervention_name>
    <description>Initially patients were to be treated with Olmesartanmedoxomil (OM) /Hydrochlorothiazide (HCTZ)40/12.5 mg tablets once daily for 8 weeks. After 8 weeks non-responders were to be uptitrated to OM/HCTZ 40/25 mg and responders remained on the previous therapy for further 8 weeks.</description>
    <arm_group_label>OM/HCTZ 40/12.5</arm_group_label>
    <other_name>Treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with a diagnosis of essential hypertension, either treatment-naive or&#xD;
             including currently on anti-hypertensive medication (in Italy only treatment naive&#xD;
             patients) in whom it is medically justifiable to withdraw treatment , and who are&#xD;
             likely to meet the required BP inclusion criteria at randomisation:&#xD;
&#xD;
               -  Mean sitting dBP ≥ 100 mmHg and ≤ 120 mmHg.&#xD;
&#xD;
               -  Mean sitting sBP ≥ 160 mmHg and ≤ 200 mmHg.&#xD;
&#xD;
        Main Exclusion Criteria:&#xD;
&#xD;
          -  Mean sitting sBP values &gt; 200 mmHg and/or dBP &gt; 120 mmHg.&#xD;
&#xD;
          -  Pregnant or nursing women.&#xD;
&#xD;
          -  Patients with serious disorders which may limit the ability to evaluate the efficacy&#xD;
             or safety of the tested medication, including cerebrovascular, cardiovascular, renal,&#xD;
             respiratory, hepatic, gastrointestinal, endocrine or metabolic, haematological,&#xD;
             oncological, neurological, and psychiatric diseases. The same applies for&#xD;
             immunocompromised and/or neutropenic patients.&#xD;
&#xD;
          -  Patients with secondary hypertension of any aetiology such as renal disease,&#xD;
             pheochromocytoma, or Cushing's syndrome.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roberto Fogari, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Clinic Policlinico San Matteo University of Pavia Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Rijeka</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Slavonski Brod</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Split</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Varaždin</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zadar</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zagreb</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Benatky nad Jizerou</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bilovec</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brodce</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jablonec nad Nisou</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mlada Boleslav</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Praha</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rokycany</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tabor</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Teplice</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Unicov</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aalborg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ballerup</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vejle</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Einbeck</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Giengen an der Brenz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Großheirath</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hanau</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Köln</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Künzing</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lollar</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nürnberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ashkelon</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beer Sheva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kfar Saba</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nahariya</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Petach Tikva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tel-Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tel-Hashomer</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Busto Arsizio</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ferrara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Daniele del Friuli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sassari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Somma Lombardo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Venezia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Białystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gdańsk</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gdynia</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Płock</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wąbrzeżno</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baia-Mare</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Braila</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cluj</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oradea</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Suceava</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Croatia</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Romania</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <study_first_submitted>February 27, 2007</study_first_submitted>
  <study_first_submitted_qc>February 27, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 28, 2007</study_first_posted>
  <results_first_submitted>May 6, 2021</results_first_submitted>
  <results_first_submitted_qc>July 8, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 28, 2021</results_first_posted>
  <last_update_submitted>July 8, 2021</last_update_submitted>
  <last_update_submitted_qc>July 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Essential Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Participants who completed the arms OM 40 mg and OM/HCTZ 40/12.5 mg, respectively in Phase A are the same ones who started, depending on being a responder or non-responder in the arms of Phase B continuing with OM 40 mg and OM/HCTZ 40/12.5 mg or uptitration to OM/HCTZ 40/12.5 mg and OM/HCTZ 40/25, respectively of Phase B.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Phase A/OM 40</title>
          <description>Olmesartanmedoxomil (OM)40 mg tablets. OM 40: Initially patients were to be treated with Olmesartanmedoxomil (OM)40 mg tablets once daily for 8 weeks. After 8 weeks non-responders were to be uptitrated to OM/HCTZ 40/12.5 mg and responders remained on the previous therapy for further 8 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Phase A/OM/HCTZ 40/12.5</title>
          <description>Olmesartanmedoxomil (OM) /Hydrochlorothiazide (HCTZ)40/12.5 mg tablets. OM/HCTZ 40/12.5: Initially patients were to be treated with Olmesartanmedoxomil (OM) /Hydrochlorothiazide (HCTZ)40/12.5 mg tablets once daily for 8 weeks. After 8 weeks non-responders were to be uptitrated to OM/HCTZ 40/25 mg and responders remained on the previous therapy for further 8 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Phase B/ OM 40 mg Responders</title>
          <description>Phase B (second double-blind treatment phase, 8 weeks duration):&#xD;
Responders to OM 40 mg treatment were to continue treatment with OM 40 mg.</description>
        </group>
        <group group_id="P4">
          <title>Phase B/ OM 40 mg Non-responder</title>
          <description>Phase B (second double-blind treatment phase, 8 weeks duration):&#xD;
Non-responders to OM 40 mg treatment were to be up-titrated to OM/HCTZ 40/12.5 mg.</description>
        </group>
        <group group_id="P5">
          <title>Phase B OM/HCTZ 40/12.5 mg Responders</title>
          <description>Phase B (second double-blind treatment phase, 8 weeks duration):&#xD;
Responders to OM/HCTZ 40/12.5 mg treatment were to continue treatment with OM/HCTZ 40/12.5 mg.</description>
        </group>
        <group group_id="P6">
          <title>Phase B/ OM/HCTZ 40/12.5 mg Non-responders</title>
          <description>Phase B (second double-blind treatment phase, 8 weeks duration):&#xD;
Non-responders to OM/HCTZ 40/12.5 mg treatment were to be up- titrated to OM/HCTZ 40/25 mg.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Phase A: Randomization to Week 8</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="285"/>
                <participants group_id="P2" count="561"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="268"/>
                <participants group_id="P2" count="524"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="37"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Phase B: Week 8 to Week 16</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="129"/>
                <participants group_id="P4" count="139"/>
                <participants group_id="P5" count="336"/>
                <participants group_id="P6" count="188"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="128"/>
                <participants group_id="P4" count="137"/>
                <participants group_id="P5" count="333"/>
                <participants group_id="P6" count="186"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>OM 40</title>
          <description>Olmesartanmedoxomil (OM)40 mg tablets.&#xD;
OM 40: Initially patients were to be treated with Olmesartanmedoxomil (OM)40 mg tablets once daily for 8 weeks. After 8 weeks non-responders were to be uptitrated to OM/HCTZ 40/12.5 mg and responders remained on the previous therapy for further 8 weeks.</description>
        </group>
        <group group_id="B2">
          <title>OM/HCTZ 40/12.5</title>
          <description>Olmesartanmedoxomil (OM) /Hydrochlorothiazide (HCTZ)40/12.5 mg tablets.&#xD;
OM/HCTZ 40/12.5: Initially patients were to be treated with Olmesartanmedoxomil (OM) /Hydrochlorothiazide (HCTZ)40/12.5 mg tablets once daily for 8 weeks. After 8 weeks non-responders were to be uptitrated to OM/HCTZ 40/25 mg and responders remained on the previous therapy for further 8 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="285"/>
            <count group_id="B2" value="561"/>
            <count group_id="B3" value="846"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="211"/>
                    <measurement group_id="B2" value="454"/>
                    <measurement group_id="B3" value="665"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                    <measurement group_id="B2" value="107"/>
                    <measurement group_id="B3" value="181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.0" spread="11.46"/>
                    <measurement group_id="B2" value="55.5" spread="10.57"/>
                    <measurement group_id="B3" value="55.6" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="128"/>
                    <measurement group_id="B2" value="267"/>
                    <measurement group_id="B3" value="395"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="157"/>
                    <measurement group_id="B2" value="294"/>
                    <measurement group_id="B3" value="451"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Trough Sitting dBP</title>
          <description>Sitting diastolic blood pressure at baseline</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="104.5" spread="4.0"/>
                    <measurement group_id="B2" value="104.6" spread="4.2"/>
                    <measurement group_id="B3" value="104.6" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Trough Sitting sBP</title>
          <description>Sitting systolic blood pressure</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="168.0" spread="7.7"/>
                    <measurement group_id="B2" value="168.5" spread="8.4"/>
                    <measurement group_id="B3" value="168.3" spread="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg.m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.64" spread="4.8"/>
                    <measurement group_id="B2" value="29.17" spread="4.665"/>
                    <measurement group_id="B3" value="29.35" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>dBP Change After 8 Weeks Phase A</title>
        <description>Reduction in Mean Trough Sitting dBP (mmHg) from Baseline (Week 0) to Week 8</description>
        <time_frame>Eight weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OM 40</title>
            <description>Olmesartanmedoxomil (OM)40 mg tablets. OM 40: Initially patients were to be treated with Olmesartanmedoxomil (OM)40 mg tablets once daily for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>OM/HCTZ 40/12.5</title>
            <description>Olmesartanmedoxomil (OM) /Hydrochlorothiazide (HCTZ)40/12.5 mg tablets. OM/HCTZ 40/12.5: Initially patients were to be treated with Olmesartanmedoxomil (OM) /Hydrochlorothiazide (HCTZ)40/12.5 mg tablets once daily for 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>dBP Change After 8 Weeks Phase A</title>
          <description>Reduction in Mean Trough Sitting dBP (mmHg) from Baseline (Week 0) to Week 8</description>
          <units>mmHG</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="282"/>
                <count group_id="O2" value="556"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.8" spread="9.71"/>
                    <measurement group_id="O2" value="-18.9" spread="9.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>sBP Change After 8 Weeks Phase A</title>
        <description>Reduction in Mean Trough Sitting sBP (mmHg) from Baseline (Week 0) to Week 8</description>
        <time_frame>Eight weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OM 40</title>
            <description>Olmesartanmedoxomil (OM)40 mg tablets. OM 40: Initially patients were to be treated with Olmesartanmedoxomil (OM)40 mg tablets once daily for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>OM/HCTZ 40/12.5</title>
            <description>Olmesartanmedoxomil (OM) /Hydrochlorothiazide (HCTZ)40/12.5 mg tablets. OM/HCTZ 40/12.5: Initially patients were to be treated with Olmesartanmedoxomil (OM) /Hydrochlorothiazide (HCTZ)40/12.5 mg tablets once daily for 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>sBP Change After 8 Weeks Phase A</title>
          <description>Reduction in Mean Trough Sitting sBP (mmHg) from Baseline (Week 0) to Week 8</description>
          <units>mmHG</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="282"/>
                <count group_id="O2" value="556"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.5" spread="14.56"/>
                    <measurement group_id="O2" value="-31.9" spread="14.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>dBP Change After 8 Weeks Phase B</title>
        <description>Reduction in trough sitting diastolic blood pressure after 8 weeks of additional treatment, depending on Phase A treatment and outcome (responder/non-responder).</description>
        <time_frame>Eight weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OM 40 mg Responders</title>
            <description>Phase B (second double-blind treatment phase, 8 weeks duration):&#xD;
Responders to OM 40 mg treatment were to continue treatment with OM 40 mg.</description>
          </group>
          <group group_id="O2">
            <title>OM 40 mg Non-responders</title>
            <description>Phase B (second double-blind treatment phase, 8 weeks duration):&#xD;
Non-responders to OM 40 mg treatment were to be up-titrated to OM/HCTZ 40/12.5 mg.</description>
          </group>
          <group group_id="O3">
            <title>OM/HCTZ 40/12.5 mg Responders</title>
            <description>Phase B (second double-blind treatment phase, 8 weeks duration):&#xD;
Responders to OM/HCTZ 40/12.5 mg treatment were to continue treatment with OM/HCTZ 40/12.5 mg.</description>
          </group>
          <group group_id="O4">
            <title>OM/HCTZ 40/12.5 mg Non-responders</title>
            <description>Phase B (second double-blind treatment phase, 8 weeks duration):&#xD;
Non-responders to OM/HCTZ 40/12.5 mg treatment were to be up- titrated to OM/HCTZ 40/25 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>dBP Change After 8 Weeks Phase B</title>
          <description>Reduction in trough sitting diastolic blood pressure after 8 weeks of additional treatment, depending on Phase A treatment and outcome (responder/non-responder).</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="129"/>
                <count group_id="O2" value="139"/>
                <count group_id="O3" value="336"/>
                <count group_id="O4" value="187"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="6.95"/>
                    <measurement group_id="O2" value="-9.3" spread="7.91"/>
                    <measurement group_id="O3" value="-0.3" spread="6.68"/>
                    <measurement group_id="O4" value="-8.0" spread="8.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>sBP Change After 8 Weeks Phase B</title>
        <description>Reduction in trough sitting systolic blood pressure after 8 weeks of additional treatment, depending on Phase A treatment and outcome (responder/non-responder).</description>
        <time_frame>Eight weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OM 40 mg Responders</title>
            <description>Phase B (second double-blind treatment phase, 8 weeks duration):&#xD;
Responders to OM 40 mg treatment were to continue treatment with OM 40 mg.</description>
          </group>
          <group group_id="O2">
            <title>OM 40 mg Non-responders</title>
            <description>Phase B (second double-blind treatment phase, 8 weeks duration):&#xD;
Non-responders to OM 40 mg treatment were to be up-titrated to OM/HCTZ 40/12.5 mg.</description>
          </group>
          <group group_id="O3">
            <title>OM/HCTZ 40/12.5 mg Responders</title>
            <description>Phase B (second double-blind treatment phase, 8 weeks duration):&#xD;
Responders to OM/HCTZ 40/12.5 mg treatment were to continue treatment with OM/HCTZ 40/12.5 mg.</description>
          </group>
          <group group_id="O4">
            <title>OM/HCTZ 40/12.5 mg Non-responders</title>
            <description>Phase B (second double-blind treatment phase, 8 weeks duration):&#xD;
Non-responders to OM/HCTZ 40/12.5 mg treatment were to be up- titrated to OM/HCTZ 40/25 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>sBP Change After 8 Weeks Phase B</title>
          <description>Reduction in trough sitting systolic blood pressure after 8 weeks of additional treatment, depending on Phase A treatment and outcome (responder/non-responder).</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="129"/>
                <count group_id="O2" value="139"/>
                <count group_id="O3" value="336"/>
                <count group_id="O4" value="187"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="6.95"/>
                    <measurement group_id="O2" value="-12.4" spread="11.64"/>
                    <measurement group_id="O3" value="-0.4" spread="9.32"/>
                    <measurement group_id="O4" value="-12.1" spread="12.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The study consisted of two sequential phases A and B of 8 weeks duration each.</time_frame>
      <desc>Adverse events were recorded for all patients who started each of the 2 treatment groups in phase A, as well as in all those patients who, as per their allocation, started the treatment groups in phase B.</desc>
      <group_list>
        <group group_id="E1">
          <title>Phase B OM/HCTZ 40/12.5 mg Non-responders</title>
          <description>Phase B (second double-blind treatment phase, 8 weeks duration):&#xD;
Non-responders to OM/HCTZ 40/12.5 mg treatment were to be up- titrated to OM/HCTZ 40/25 mg.</description>
        </group>
        <group group_id="E2">
          <title>Phase B OM/HCTZ 40/12.5 mg Responders</title>
          <description>Phase B (second double-blind treatment phase, 8 weeks duration):&#xD;
Responders to OM/HCTZ 40/12.5 mg treatment were to continue treatment with OM/HCTZ 40/12.5 mg.</description>
        </group>
        <group group_id="E3">
          <title>Phase B OM 40 mg Non-responders</title>
          <description>Phase B (second double-blind treatment phase, 8 weeks duration):&#xD;
Non-responders to OM 40 mg treatment were to be up-titrated to OM/HCTZ 40/12.5 mg.</description>
        </group>
        <group group_id="E4">
          <title>Phase B OM 40 mg Responders</title>
          <description>Phase B (second double-blind treatment phase, 8 weeks duration):&#xD;
Responders to OM 40 mg treatment were to continue treatment with OM 40 mg.</description>
        </group>
        <group group_id="E5">
          <title>Phase A OM/HCTZ 40/12.5 mg</title>
          <description>Phase A (first double-blind treatment phase, 8 weeks duration):&#xD;
Arm 2: OM/HCTZ 40/12.5 mg tablet o.d.</description>
        </group>
        <group group_id="E6">
          <title>Phase A OM 40 mg</title>
          <description>Phase A (first double-blind treatment phase, 8 weeks duration):&#xD;
Arm 1: OM 40 mg tablet o.d.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="129"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="561"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="285"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="285"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="561"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="285"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="561"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Parotid abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Erysipeloid</sub_title>
                <description>Erysipel B / Erysipel Crus Left</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="285"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Anal fissure</sub_title>
                <description>Worsening and surgery</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="285"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="285"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="561"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="285"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ischaemic cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="561"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Brain contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="285"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="129"/>
                <counts group_id="E5" subjects_affected="41" subjects_at_risk="561"/>
                <counts group_id="E6" subjects_affected="19" subjects_at_risk="285"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="129"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="336"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="188"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="336"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="129"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="561"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="336"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="139"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="129"/>
                <counts group_id="E5" events="14" subjects_affected="14" subjects_at_risk="561"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="285"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="188"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="336"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="188"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E5" events="10" subjects_affected="10" subjects_at_risk="561"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="336"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="139"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E5" events="9" subjects_affected="9" subjects_at_risk="561"/>
                <counts group_id="E6" events="6" subjects_affected="6" subjects_at_risk="285"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="561"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="285"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="188"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="336"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="561"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="285"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Angela Capriati, MD PhD - Global Director Clinical Sciences</name_or_title>
      <organization>Menarini Group</organization>
      <phone>+39 055 5680 ext 9990</phone>
      <email>acapriati@menarini-ricerche.it</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

